Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

l function at low concentrations of Dimebon across multiple experiments, and Dimebon showed potent mitochondrial responses in both stressed and normal cells.

MDV3100

  • Completed enrollment in our Phase 1-2 dose-escalation trial in patients with castration-resistant prostate cancer (CRPC).
  • Presented data from our Phase 1-2 clinical trial at ASCO's 2009 Genitourinary Cancers Symposium showing that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels, endpoints and in both pre- and post-chemotherapy groups in the 114 patients who had thus far been followed for 12 weeks or longer. Safety data demonstrated that doses at 240 mg and below were well tolerated.
  • Remain on track to seek FDA approval to begin a pivotal Phase 3 registration study in castration-resistant prostate cancer patients in 2009.
  • Will present additional data from the ongoing Phase 1-2 study at upcoming medical conferences in 2009.

Fourth Quarter and Year-End 2008 Financial Results

Revenue for the fourth quarter and full year of 2008 was $12.6 million, consisting of partial recognition of the non-refundable up-front payment of $225.0 million received from Pfizer in October 2008. The up-front payment was recorded as deferred revenue upon receipt and is being recognized on a straight-line basis over the estimated performance period of the Company's obligations under its collaboration agreement with Pfizer, which the Company presently expects to complete in the first quarter of 2012.

For the twelve months ended December 31, 2008, total operating expenses were $76.8 million, compared with total operating expenses of $33.8 million for the same period in 2007. These figures include non-cash stock-based compensation expense of $8.5 million in the year ended December 3
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... The Netherlands and BARCELONA, Spain, July 15, Agendia ... will give Ferrer exclusive rights to sell two ... prognostic test,that uses a 70-gene signature to indicate ... gene expression profiling service which offers,a fast and ...
... Schizophrenia is a disease that strikes an average ... psychiatric disorder are not yet clear. But now, VIB ... that a disturbed cleavage of the Nrg-1 protein lies ... Greater understanding of this molecular process is a first ...
... to Host Conference Call to Update Clinical Program ... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it ... clinical studies with,REOLYSIN(R), its proprietary formulation of the ... substantial momentum in the past year,culminating in the ...
Cached Biology Technology:Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets 2Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets 3Incorrectly cleaved protein leads to schizophrenia 2Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 2Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 3
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... The world,s top scientists and clinicians in the ... present their latest research findings at the 60th Annual ... Tuesday, November 2, through Saturday, November 6, 2010, at ... Founded in 1948, the American Society of Human Genetics ...
... 2010 The American Society of Agronomy (ASA), Crop ... of America (SSSA) will present the following 2010 Scholarships ... 3 in Long Beach, CA, www.acsmeetings.org . ... The Hank Beachell Future Leader Scholarship, funded through ...
... stem (hPS) cells can generate any given cell type ... are of interest to stem cell scientists working on ... heart disease, diabetes, arthritis, and other ailments. Before ... however, some obstacles must first be overcome. One ...
Cached Biology News:American Society of Human Genetics to host 60th Annual Meeting in Washington, D.C. 2American Society of Human Genetics to host 60th Annual Meeting in Washington, D.C. 3ASA, CSSA and SSSA present scholarships and fellowships 2ASA, CSSA and SSSA present scholarships and fellowships 3ASA, CSSA and SSSA present scholarships and fellowships 4ASA, CSSA and SSSA present scholarships and fellowships 5ASA, CSSA and SSSA present scholarships and fellowships 6ASA, CSSA and SSSA present scholarships and fellowships 7ASA, CSSA and SSSA present scholarships and fellowships 8ASA, CSSA and SSSA present scholarships and fellowships 9Researchers at UC Riverside find solution to cell death problem vexing stem cell research 2
... Afinity Purified Tyrosine Hydroxylase (Ser40) ... was raised against synthetic phosphopeptide ... surrounding the phospho-Ser40 of rat ... was purified by sequential chromatography ...
NF kappa B Related Sampler Kit 10g each...
... Kits synthesize RNA probes with specific activities ... High specific activity, single-stranded RNA probes are ... hybridization, and blot hybridizations. MAXIscript Kits can ... modest amounts of unlabeled RNA (2-4 g/20ul ...
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Biology Products: